Regulatory reference
Are peptides legal in the US? The FDA position, stated plainly
Peptide regulation moved twice in 2026, and most coverage of it is wrong in the same direction — treating a committee recommendation as though it were an approval. This page separates what happened from what did not.
The five stages, and where the story actually is
Almost every confusion about peptide legality collapses into one thing: treating an earlier stage as though it were the last one.
01
Nominated
Someone proposes the substance for compounding use.
02
Category 2
FDA flags significant safety risks pending evaluation.
03
Nomination withdrawn
The nominator pulls it. FDA still publishes its risk language.
04 Here
Advisory committee
A non-binding recommendation. Not a decision.
05
On the 503A Bulks List
The only stage that confers authority. Reached by rulemaking.
What happened in July 2026
On 23–24 July 2026 the FDA's Pharmacy Compounding Advisory Committee met at the agency's White Oak campus and considered seven substances for inclusion on the 503A Bulks List — the list that determines what compounding pharmacies may lawfully use. The substances were BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax and epitalon.
That is the whole of what occurred. FDA's own description of what such a meeting means is worth quoting exactly:
“Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so.” — U.S. Food and Drug Administration
What the committee decided — and who says so
FDA has published no vote tally. Regulatory trade press (RAPS) reports the committee voted 8–6 with one abstention to recommend BPC-157, KPV, TB-500 and MOTS-c for the 503A list, and reports that emideltide was not recommended — reportedly against FDA staff’s written recommendation, which cited a lack of evidence to support effectiveness. Treat this as press-reported, not as an FDA decision.
Even taking the reported vote at face value, nothing has changed for a patient or a buyer today. The 503A Bulks List is amended by FDA through rulemaking, not by a committee show of hands, and as of the FDA pages we checked no peptide has been added.
The detail almost every article omits
FDA published the specific use it evaluated for each substance. In several cases that use is not the use the substance is marketed for. BPC-157 is sold overwhelmingly for tendon, ligament and joint repair. The use FDA assessed was ulcerative colitis.
| Substance | Forms considered | Use FDA evaluated | Session |
|---|---|---|---|
| BPC-157 | free base / acetate | Ulcerative colitis | 2026-07-23 |
| KPV | free base / acetate | Wound healing and inflammatory conditions | 2026-07-23 |
| TB-500 | free base / acetate | Wound healing | 2026-07-23 |
| MOTS-c | free base / acetate | Obesity and osteoporosis | 2026-07-23 |
| Emideltide (DSIP) | free base / acetate | Opioid withdrawal, chronic insomnia | 2026-07-24 |
| Semax | free base / acetate | See the FDA briefing document | 2026-07-24 |
| Epitalon | free base / acetate | See the FDA briefing document | 2026-07-24 |
What the “503A Bulks List” actually contains
Almost every article about this uses the phrase without saying what is on it. The list is codified in federal regulation at 21 CFR 216.23(a), and it has six entries:
Brilliant Blue G (Coomassie Brilliant Blue G-250)Cantharidin (topical use only)Diphenylcyclopropenone (topical use only)N-acetyl-D-glucosamine (topical use only)Squaric acid dibutyl ester (topical use only)Thymol iodide (topical use only)
No peptide appears on the 503A Bulks List. As of August 2026, none has completed the notice-and-comment rulemaking that would put one there.
The categories 1, 2 and 3 that dominate the coverage are something else: buckets under an interim enforcement-discretion policy while FDA works through nominations. Being in category 1 is not the same as being on the list, and only the list carries legal authority.
“Category 2” — what is actually on it
FDA maintains a page of bulk drug substances that “may present significant safety risks” in compounding. Coverage of peptides routinely says BPC-157 and TB-500 were removed from it. That is not what the page shows.
The page has two parts. One is the live category-2 table. The other is headed “bulk drug substances nominated but withdrawn” — substances whose nominations the nominators withdrew. FDA still publishes its risk language for those substances. A withdrawn nomination is not a clearance.
Currently in category 2 (peptide-relevant entries)
| Substance | List | Added | FDA's stated risk |
|---|---|---|---|
| Growth hormone releasing peptide-2 (GHRP-2), injectable and nasal | 503B | 2023-09-29 | FDA cites risk of immunogenicity from aggregation and peptide-related impurities; also notes it contains an unnatural amino acid. |
| Growth hormone releasing peptide-6 (GHRP-6) | 503B | 2023-09-29 | FDA cites potential effect on cortisol and increased blood glucose from decreased insulin sensitivity. |
| Ibutamoren mesylate | 503A and 503B | 503A: 2023-09-29 · 503B: 2022-12-29 | FDA cites potential for congestive heart failure in certain patients. |
| Ipamorelin acetate | 503B | 2023-09-29 | FDA cites serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility. |
| Kisspeptin-10 | 503A | 2023-09-29 | FDA states it has no, or only limited, safety-related information for the proposed routes of administration. |
Listed as nominated but withdrawn
FDA publishes no dates for these entries. Their presence in this section means a nomination was withdrawn — nothing more. FDA still publishes its risk language for each.
AOD-9604BPC-157Cathelicidin LL-37CJC-1295Dihexa acetateEmideltide (DSIP)EpitalonGHK-Cu (injectable)Ipamorelin acetateKPVMelanotan IIMOTS-cPEG-MGFSelank acetate (TP-7)Semax (heptapeptide)Thymosin-alpha 1TB-500 (thymosin beta-4 fragment LKKTETQ)
Ipamorelin acetate is the one substance in both tables. FDA annotates the duplication directly on its page: the nomination was withdrawn, and it separately remains a category-2 entry under the interim policies.
Five claims, checked
“These peptides are now legal, or FDA-approved.” Not supported
FDA states that advisory committees make non-binding recommendations. A recommendation is not an approval, and FDA has not published an outcome for this meeting.
“Compounding pharmacies may now prepare these substances.” Not supported
Inclusion on the 503A Bulks List is the step that would permit that. The committee meeting is an input to that decision, not the decision itself.
“BPC-157 and TB-500 were removed from FDA’s Category 2 safety-risk list.” Misleading
They appear on FDA’s page under "bulk drug substances nominated but withdrawn" — the nominations were withdrawn by the nominators. FDA still publishes its risk language for each. That is not the same as FDA clearing a substance.
“FDA evaluated these substances for the uses they are marketed for.” Not supported
FDA published the specific use it reviewed for each. BPC-157 was evaluated for ulcerative colitis, not tendon or ligament repair — the use it is most often marketed for. TB-500 was evaluated for wound healing, not athletic recovery.
“FDA reviewed these substances for possible inclusion on the 503A Bulks List in July 2026.” Supported
Stated on the FDA advisory-committee meeting page, with substances and evaluated uses in the published agenda under docket FDA-2025-N-6895.
Enforcement did not pause while this was happening
Between December 2024 and June 2026, FDA issued warning letters to firms selling peptides and related products directly to the public. We hold 14 of those documents, each linked to fda.gov. The most recent is dated 2026-06-17.
The letters matter for a practical reason: a substance being discussed for possible compounding use has no bearing on whether a website may sell it to consumers today. Those are separate questions under separate parts of the law.
Read the dated warning-letter archiveGLP-1 medicines are not prohibited in sport
Semaglutide, tirzepatide and retatrutide appear nowhere on the WADA 2026 Prohibited List — not in competition, not out of competition, in no section. Semaglutide and tirzepatide are on the separate Monitoring Program, and WADA states in its own footnote that the programme covers substances "which are not on the Prohibited List". Monitoring is not prohibition. Retatrutide appears in neither document.
The contrast with the growth-hormone peptides is stark: sermorelin sits on no FDA compounding restriction at all, yet is named on the Prohibited List and banned at all times. FDA compoundability and WADA legality are independent axes, and a substance can be unrestricted on one and prohibited on the other.
Common questions
Are peptides legal in the United States?
The question has no single answer because "peptides" covers several regulatory categories at once. Some peptide medicines are FDA-approved for named indications. Some are prescribed off-label. Some are compounded, which means they are not FDA-approved. And many widely marketed peptides have no approved human use at all. The category a specific substance falls into is what determines how it may lawfully be supplied.
Did the FDA approve BPC-157 in July 2026?
No. An FDA advisory committee met on 23–24 July 2026 and considered BPC-157 and several other substances for inclusion on the 503A Bulks List, which governs what compounding pharmacies may use. FDA states that advisory committees make non-binding recommendations. A recommendation is not an approval, and it is not the same as a substance being added to that list.
What does "research use only" mean legally?
It describes an intended use, not a legal shield. FDA assesses the whole marketing context. In the warning letters archived on this site, firms selling products labelled for research use were still told the products were unapproved new drugs offered for sale in the United States — in several cases while the products were listed under coded names rather than the drug name.
Which peptide medicines are FDA-approved?
Several are, for specific named indications — including semaglutide and tirzepatide for their approved uses, tesamorelin for HIV-associated lipodystrophy, and bremelanotide for one indication in one population. Approval is always for a named use in a named population, never for a substance in general.
Can a doctor prescribe a peptide that is not FDA-approved?
A clinician may lawfully prescribe an approved medicine off-label when they judge it appropriate. That is different from a substance with no approved human indication at all, which cannot simply be prescribed off-label because there is no approval to depart from. Ask a clinic which of the two situations applies to anything it proposes.
What this page deliberately omits
Nothing here tells you how to obtain any substance, in what quantity, or by what route. Regulatory status is not a treatment recommendation, and a substance moving closer to compounding eligibility says nothing about whether it is appropriate for any individual. That judgment belongs with a licensed clinician who has evaluated you.